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Resolution of Pregabalin and Mirtazapine Associated 
Restless Legs Syndrome by Bupropion in a Patient   
with Major Depressive Disorder 
 
 
 
Bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no seroto-
nergic activity, and is therefore an antidepressant with unique pharmacological properties. 
There are some reports that selective serotonin reuptake inhibitors (SSRIs) or mirtazapine 
can induce adverse effects including restless legs syndrome (RLS) and that bupropion can 
reverse these adverse effects. Here, we report about a patient with a major depressive dis-
order who exhibited RLS after being treated with pregabalin and mirtazapine. This adverse 
effect disappeared after having switched from mirtazapine to bupropion. Bupropion inhibits 
the reuptake of dopamine and increases dopamine neurotransmission in both the nucleus 
accumbens and the prefrontal cortex. This pharmacological profile can be effective in pa-
tients with RLS related to dopamine hypoactivity. However, the limitations of this single 
case report mean that further investigations with larger samples are needed. 
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Introduction 
 
Restless legs syndrome (RLS), which is characterized by an unpleasant sensation 
in the legs that results in an urge to move them, is often either undiagnosed or mis-
diagnosed as a psychiatric, other neurological, muscular, or orthopedic condition. RLS
is also characterized by worsening of symptoms at rest and in the evening or night.
Many patients with RLS also exhibit periodic limb movement during sleep and re-
laxed wakefulness.
1 This disorder can cause severe insomnia and mood disturbances, 
and has an adverse impact on the patient’s quality of life.
 2 The cause of RLS is not yet 
clear, but one of the more promising theories involves the body’s dopamine system.
Most RLS cases are idiopathic. Secondary RLS is observed in the patients with dia-
betes mellitus, renal failure, iron-deficiency anemia, polyneuropathy, and rheumatoid 
arthritis.
3 Medication-induced RLS remains an underdiagnosed etiology of secon-
dary RLS. However, antidepressants have long been known to exacerbate RLS.
4 
The prescription of the new antidepressants such as, selective serotonin reuptake
inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and nor-
adrenergic and specific serotonergic antidepressants (NaSSAs), is increasing com-
pared to that of tricyclic antidepressants. These antidepressants have become a first-
line treatment option for millions of patients due to their good balance between ef-
ficacy and tolerability. However, some adverse effects associated with their use such
as, weight gain, sexual dysfunction, RLS, and emotional detachment, can impair the
quality of life and compliance with treatment.
5,6 Because it appears that these adverse  
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effects are mainly associated with serotonin, many clini-
cians have moved toward the use of bupropion. Buprop-
ion does not affect serotonin or postsynaptic receptors, 
and it is therefore an antidepressant with unique phar-
macological properties.
7 There are some reports that SSRIs 
or mirtazapine can induce RLS and that bupropion can 
reverse this adverse effect.
8 Here, we report about a pa-
tient with a major depressive disorder who exhibited RLS 
after being treated with pregabalin and mirtazapine. This 
adverse effect disappeared after having switched from 
mirtazapine to bupropion. 
 
Case 
 
A 64-year-old Korean female was admitted to our hos-
pital in 2003 due to the onset of a depressive episode. She 
had been treated by a local psychiatric practitioner with 
sertraline for 15 years. The presenting symptoms were 
suicidal ideation, avolition, insomnia, depressed mood, 
and fatigue. During her admission, we replaced sertraline 
with mirtazapine. Her acute symptomatology had largely 
remitted after 1 month of hospital treatment, and hence 
she was discharged to day-clinic treatment. We maintain-
ed her on 15-45 mg of mirtazapine daily for 5 years, with 
the daily dose being reduced to 15 mg because of her 
stability.  
Her general practitioner prescribed pregabalin at 300 
mg/day due to shoulder and back pain in April 2008, and 
this induced an uncomfortable sensation in both legs at 
rest 1 week later. The unpleasant sensation worsened at 
night and could be relieved by moving the legs. The pa-
tient met the diagnostic criteria for RLS published by 
the International RLS Study Group (IRLSSG).
9 The se-
verity of her RLS symptoms was scored as 26 points on 
RLS rating scale,
10 which comprises 10 items scored from 
0 to 4 points with highest possible score of 40 points. 
She did not have any other disease related to secondary 
RLS. She also had no organic brain disease and was tak-
ing no medication except mirtazapine and pregabalin. All 
of her routine laboratory parameters including iron (125 
μg/dL), ferritin (81 ng/mL), and TIBC (234 μg/dL) were 
within normal limits. We recommended her to stop taking 
pregabalin, but she refused because it was effective ag-
ainst her shoulder and back pain.   
To treat her RLS, in May 2008 we replaced mirtaza-
pine with bupropion SR at 150 mg daily, but we could not 
discontinue pregabalin because she wanted to continue it. 
The patient’s RLS symptoms improved substantially such 
that by day 28 following commencement of bupropion 
SR therapy, her RLS symptom score was 14 points. Her 
RLS symptoms totally disappeared in August 2008 when 
we increased bupropion to 300 mg (Wellbutrin XL) daily. 
Her score had decreased to zero. She did not report any 
other RLS symptoms. The follow-up visit 1 month re-
vealed no further symptoms of RLS.   
 
Discussion 
 
Bupropion is the only antidepressant that exerts effects 
on both norepinephrine and dopamine neurotransmitters 
with no known serotonergic activity.
11 Thus, unlike SSRIs 
and mirtazapine, it is not associated with adverse effects 
such as RLS and sexual dysfunction. Indeed, bupropion 
can reverse these conditions by altering dopaminergic ac-
tivity.
5,6 
It was reported that RLS was a common side effect 
(28%) during application of mirtazapine.
4 After the ad-
ministration of mirtzapine and pregabalin, her RLS symp-
toms had appeared. Thus, this might be the first case 
supporting the hypothesis that the combined administ-
ration of mirtazapine and pregabalin is related to the on-
set of RLS. However, it is also possible that pregabalin 
alone is responsible for the onset of RLS because mir-
tazapine alone, when administered from 2003 to 2008, 
did not cause any RLS symptoms. She did not experi-
ence RLS symptoms during mirtazapine treatment, but 
these presented immediately after she was treated with 
pregabalin in April 2008. Therefore, it is possible that 
pregabalin can induce RLS. However, it remains open as 
to whether the combination or even pregabalin alone is 
responsible for RLS. 
There has been a single case report of pregabalin in-
ducing myoclonus,
12 but there has been no previous re-
port of pregabalin inducing RLS. However, pregabalin 
could theoretically induce RLS because it binds potently 
to the α2-δ subunit and modulates calcium influx at nerve 
terminals, and thereby reduces the release of several neu-
rotransmitters including glutamate, norepinephrine, se-
rotonin, dopamine, and substance P.
13-17 Furthermore, there 
has been a case report of RLS being induced by zonisa-
mide, which is a type of anticonvulsant like pregabalin.
18 
However, it was reported that pregabalin was effective 
in the treatment of secondary RLS for patients with neu-
ropathic pain in a recent open trial.
19 Therefore, whether 
pregabalin can induce RLS or not remains controversial. 
Bupropion inhibits the reuptake of dopamine and in-
creases dopamine neurotransmission in both the nucleus 
accumbens and the prefrontal cortex.
11 This pharmaco-
logical profile can be effective in patients with RLS re-
lated to dopamine hypoactivity.
8,20 However, it remains 
open as to whether the discontinuation of mirtazapine or 
the addition of bupropion is responsible for the impro-
vement of RLS symptoms. The limitations of this single 
case report mean that further investigations with larger  
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samples are needed. 
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